Trevena (TRVN) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Trevena's stock. Their TRVN share price forecasts range from $2.00 to $9.00. On average, they anticipate the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 356.1% from the stock's current price.
View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts.

Trevena's stock was trading at $1.43 on January 1st, 2023. Since then, TRVN shares have decreased by 15.7% and is now trading at $1.2059.
View the best growth stocks for 2023 here.

Trevena saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 752,700 shares, an increase of 341.2% from the April 30th total of 170,600 shares. Based on an average daily trading volume, of 2,500,000 shares, the short-interest ratio is currently 0.3 days. Currently, 7.1% of the company's stock are short sold.
View Trevena's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our TRVN earnings forecast.

Trevena, Inc. (NASDAQ:TRVN) released its earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.60 million. During the same period in the prior year, the business posted ($2.50) earnings per share.

Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (3.42%), Renaissance Technologies LLC (0.74%), Jane Street Group LLC (0.47%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRVN stock can currently be purchased for approximately $1.21.

Trevena (NASDAQ:TRVN) has a market capitalization of $13.23 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-53,670,000.00 in net income (profit) each year or ($6.04) on an earnings per share basis.

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.